Forma Therapeutics Holdings, Inc. (FMTX)
| Market Cap | 1.64B |
| Revenue (ttm) | 7.44M |
| Net Income (ttm) | n/a |
| Shares Out | 41.09M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $37.50 |
| Previous Close | $37.50 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 35.81 |
| Day's Range | 35.31 - 37.75 |
| Day's Volume | 485,676 |
| 52-Week Range | 32.95 - 51.08 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that renowned doctor Selwyn M. Vickers, M.D., has been elected to the company's board of directors.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the pricing of an underwritten public offering of 5,300,000 shares of its common stock.
WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics launches a proposed public offering of 4,600,000 shares of its common stock.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics presents clinical proof-of-concept data on FT-4202 in sickle cell disease at the 62nd ASH annual meeting.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces financial results for the third quarter ended September 30, 2020.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces EU Orphan Drug designation for FT-4202 for the treatment of sickle cell disease.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma announced that four abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma today announced that company management will participate in three upcoming investor conferences.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive top-line data from planned interim analysis of Phase 2 trial evaluating olutasidenib in acute myeloid leukemia.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointments of two new vice presidents
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointment of Thomas G.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that Wayne A.I.
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...
Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.
About FMTX
Forma Therapeutics Holdings, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed t... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2020 |
| CEO Frank D. Lee | Employees 89 |
| Stock Exchange NASDAQ | Ticker Symbol FMTX |
Analyst Forecasts
According to 5 analysts, the average rating for FMTX stock is "Strong Buy." The 12-month stock price forecast is 61.60, which is an increase of 64.27% from the latest price.